Bill Overview
Title: Give Kids a Chance Act of 2022
Description: Give Kids a Chance Act This bill authorizes the Food and Drug Administration (FDA) to take various actions regarding pediatric cancer treatments, such as requiring pediatric cancer trials involving a combination of drugs when an applicant seeks market approval for a new drug (or biological product).
Sponsors: Sen. Rubio, Marco [R-FL]
Target Audience
Population: children worldwide with cancer
Estimated Size: 10000
- The bill focuses on pediatric cancer treatments, specifically facilitating trials involving combinations of drugs.
- Globally, the incidence rate of pediatric cancers is approximately 140 per million children under 15.
- The bill could potentially influence cancer treatment protocols applicable worldwide as the FDA's decisions can impact global pharmaceutical practices.
- Families of children currently diagnosed with cancer worldwide could be directly affected.
Reasoning
- The target group of the policy is children undergoing cancer treatment and their families, approximately 10,000 in the U.S. As the policy aims to improve treatment options and potentially survival rates, this should positively affect their wellbeing scores.
- Other groups, such as healthcare providers, will be indirectly affected; however, the impact on their wellbeing might be minimal.
- Some families might not see immediate changes due to the time it takes for new treatments to be approved and become available.
- The policy's financial constraints suggest prioritizing trials, which could lead to competition among pharmaceutical companies and healthcare providers, likely resulting in positive long-term effects on pediatric oncology.
- Considering the distribution across the country is essential, as access to these new trials may be geographically uneven. Taking into account accessibility and socioeconomic factors is important.
Simulated Interviews
Pediatric Oncologist (New York, NY)
Age: 35 | Gender: female
Wellbeing Before Policy: 7
Duration of Impact: 10.0 years
Commonness: 15/20
Statement of Opinion:
- The policy is essential for accelerating drug development.
- It may initially increase workload but will vastly improve treatment arsenal.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 7 |
| Year 2 | 8 | 7 |
| Year 3 | 8 | 7 |
| Year 5 | 9 | 7 |
| Year 10 | 9 | 6 |
| Year 20 | 9 | 6 |
Parent (Houston, TX)
Age: 40 | Gender: male
Wellbeing Before Policy: 5
Duration of Impact: 20.0 years
Commonness: 5/20
Statement of Opinion:
- I hope this will give my son a better fighting chance.
- It can't come soon enough.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 5 |
| Year 2 | 7 | 5 |
| Year 3 | 8 | 5 |
| Year 5 | 9 | 5 |
| Year 10 | 9 | 4 |
| Year 20 | 9 | 4 |
Pharmaceutical Researcher (San Francisco, CA)
Age: 45 | Gender: female
Wellbeing Before Policy: 6
Duration of Impact: 10.0 years
Commonness: 10/20
Statement of Opinion:
- This policy aligns with our efforts for more effective therapies.
- It will foster innovation in pediatric research.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 6 |
| Year 2 | 7 | 6 |
| Year 3 | 8 | 6 |
| Year 5 | 8 | 6 |
| Year 10 | 8 | 5 |
| Year 20 | 7 | 5 |
Healthcare Policy Analyst (Chicago, IL)
Age: 29 | Gender: other
Wellbeing Before Policy: 7
Duration of Impact: 5.0 years
Commonness: 8/20
Statement of Opinion:
- Although it's a step in the right direction, continuous updates will be needed to adapt to new cancer research.
- It addresses a significant gap in pediatric treatment protocols.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 7 | 7 |
| Year 2 | 7 | 7 |
| Year 3 | 7 | 6 |
| Year 5 | 7 | 6 |
| Year 10 | 7 | 6 |
| Year 20 | 7 | 5 |
Retired Pediatrician (Atlanta, GA)
Age: 70 | Gender: male
Wellbeing Before Policy: 8
Duration of Impact: 5.0 years
Commonness: 12/20
Statement of Opinion:
- This policy could revitalize interest and funding in pediatric oncological studies.
- It's morale-boosting for practitioners dedicated to this challenging field.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 8 | 8 |
| Year 2 | 8 | 8 |
| Year 3 | 8 | 8 |
| Year 5 | 8 | 8 |
| Year 10 | 8 | 7 |
| Year 20 | 7 | 6 |
Public Health Official (Miami, FL)
Age: 50 | Gender: female
Wellbeing Before Policy: 6
Duration of Impact: 10.0 years
Commonness: 10/20
Statement of Opinion:
- The policy can reduce long-term healthcare costs by improving early treatment success.
- Local communities will need education on new treatment availability.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 6 |
| Year 2 | 7 | 6 |
| Year 3 | 7 | 6 |
| Year 5 | 8 | 6 |
| Year 10 | 8 | 6 |
| Year 20 | 7 | 5 |
Biotech Entrepreneur (Boston, MA)
Age: 37 | Gender: male
Wellbeing Before Policy: 8
Duration of Impact: 10.0 years
Commonness: 12/20
Statement of Opinion:
- This could lead to more investor interest in pediatric oncology innovations.
- We anticipate this will expand our research collaborations.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 8 | 8 |
| Year 2 | 8 | 8 |
| Year 3 | 9 | 8 |
| Year 5 | 9 | 8 |
| Year 10 | 9 | 8 |
| Year 20 | 8 | 7 |
Childhood Cancer Survivor (Los Angeles, CA)
Age: 32 | Gender: female
Wellbeing Before Policy: 8
Duration of Impact: 20.0 years
Commonness: 5/20
Statement of Opinion:
- Having gone through it, I know how important trials are for hope and survival.
- This policy could make a real difference for families like mine.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 9 | 8 |
| Year 2 | 9 | 8 |
| Year 3 | 9 | 8 |
| Year 5 | 9 | 8 |
| Year 10 | 9 | 8 |
| Year 20 | 9 | 7 |
Town Doctor (Rural Kansas)
Age: 63 | Gender: female
Wellbeing Before Policy: 6
Duration of Impact: 10.0 years
Commonness: 4/20
Statement of Opinion:
- Rural areas may lag in accessing new treatments despite the policy.
- We need more focus on practical implementation in remote regions.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 6 |
| Year 2 | 6 | 6 |
| Year 3 | 6 | 5 |
| Year 5 | 6 | 5 |
| Year 10 | 5 | 5 |
| Year 20 | 5 | 4 |
Medical Student (Seattle, WA)
Age: 28 | Gender: male
Wellbeing Before Policy: 6
Duration of Impact: 15.0 years
Commonness: 14/20
Statement of Opinion:
- The policy incentivizes our future generation of scientists to focus on emerging therapies.
- Practical experience will become more enriching with access to cutting-edge treatments.
Wellbeing Over Time (With vs Without Policy)
| Year | With Policy | Without Policy |
|---|---|---|
| Year 1 | 6 | 6 |
| Year 2 | 7 | 6 |
| Year 3 | 7 | 6 |
| Year 5 | 8 | 7 |
| Year 10 | 8 | 7 |
| Year 20 | 8 | 7 |
Cost Estimates
Year 1: $80000000 (Low: $60000000, High: $100000000)
Year 2: $82000000 (Low: $62000000, High: $102000000)
Year 3: $84000000 (Low: $64000000, High: $104000000)
Year 5: $88000000 (Low: $68000000, High: $108000000)
Year 10: $96000000 (Low: $74000000, High: $116000000)
Year 100: $150000000 (Low: $120000000, High: $200000000)
Key Considerations
- The policy could expedite the development and approval of life-saving treatments for children, providing high societal value.
- Long-term savings in healthcare could offset some initial implementation costs.
- Coordination between multiple stakeholders in the drug approval process will be essential.